- Child Neurology Society
- The Epilepsy Study Consortium (TESC)
Mayank Verma, M.D., Ph.D.
- Pediatric Neurology
- Pediatric Epilepsy
- Neurogenetic Disorders
Biography
Mayank Verma, M.D., Ph.D., is an Assistant Professor in the Department of Pediatrics at UT Southwestern Medical Center. He specializes in pediatric epilepsies, neurogenetic disorders, and pediatric neuromuscular disorders.
After earning his medical degree and a doctorate in integrative biology and physiology at the University of Minnesota Medical School, Dr. Verma completed an internship in pediatrics at Children’s Medical Center Dallas. He completed his residency in child neurology at UT Southwestern, and gained advanced training through a research fellowship in gene therapy as part of his child neurology basic neuroscience pathway under Berge Minassian, M.D. Dr. Verma joined the UT Southwestern faculty in 2025.
His lab studies progressive myoclonic epilepsy and neuronal glycogen storage disorders; rare neurological disease that have no treatment; and the high burden of disease. As both a physician and a scientist, he works to translate discoveries from animal models into improved natural history and biomarker studies, with the goal of developing gene therapy clinical trials.
Dr. Verma sees patients in the neuromuscular clinic and the epilepsy clinic.
He presents regularly on genetic testing and gene therapy programs for rare neurological diseases. Dr. Verma has published and co-authored many articles, reviews, and book chapters.
Personal Note
When he’s not at work, Dr. Verma enjoys gardening and taking walks with his family.
Education & Training
- Medical School - , Medicine
Professional Associations & Affiliations
Honors & Awards
- Dean’s Scholar in Clinical Research 2026, UT Southwestern
- Award of Excellence 2025, Children’s Health Pediatric Neurology Clinic Nurses
- Resident Excellence in Care 2025, Children’s Health Neurosciences Floor Nurses
- First Place in Basic Science 2024, Dr. Susan Iannaccone Research Day
Books & Publications
-
Publications
-
Lafora disease gene therapy: EPM2A but not EPM2B overexpression results in Lafora body formation.
Alao EO, Sheibani M, Wu J, Marriam U, Evans D, Kasiri S, Verma M, Nitschke S, Nitschke F, Gray SJ, Mitra S, Minassian BA, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2026 Mar 23 2 e00866 -
Focused ultrasound widely broadens AAV-delivered Cas9 distribution and activity.
Gumusgoz E, Kasiri S, Youssef I, Verma M, Chopra R, Villarreal Acha D, Wu J, Marriam U, Alao E, Chen X, Guisso DR, Gray SJ, Shah BR, Minassian BA, Gene therapy 2025 May 32 3 237-245 -
Glycogen synthase GYS1 overactivation contributes to glycogen insolubility and malto-oligoglucan-associated neurodegenerative disease.
Nitschke S, Montalbano AP, Whiting ME, Smith BH, Mukherjee-Roy N, Marchioni CR, Sullivan MA, Zhao X, Wang P, Mount H, Verma M, Minassian BA, Nitschke F, The EMBO journal 2025 Mar 44 5 1379-1413 -
Protocol for the three-dimensional analysis of rodent skeletal muscle.
Karthikeyan S, Asakura Y, Verma M, Asakura A, STAR protocols 2025 Mar 6 1 103549 -
Three-dimensional imaging studies in mice identify cellular dynamics of skeletal muscle regeneration.
Collins BC, Shapiro JB, Scheib MM, Musci RV, Verma M, Kardon G, Developmental cell 2024 Jun 59 11 1457-1474.e5 -
CSTB gene replacement improves neuroinflammation, neurodegeneration and ataxia in murine type 1 progressive myoclonus epilepsy.
Gumusgoz E, Kasiri S, Verma M, Wu J, Villarreal Acha D, Marriam U, Fyffe-Maricich S, Lin A, Chen X, Gray SJ, Minassian BA, Gene therapy 2024 May 31 5-6 234-241 -
Myofiber-type-dependent 'boulder' or 'multitudinous pebble' formations across distinct amylopectinoses.
Mitra S, Chen B, Shelton JM, Nitschke S, Wu J, Covington L, Dear M, Lynn T, Verma M, Nitschke F, Fuseya Y, Iwai K, Evers BM, Minassian BA, Acta neuropathologica 2024 Feb 147 1 46 -
VEGFR-1/Flt-1 inhibition increases angiogenesis and improves muscle function in a mouse model of Duchenne muscular dystrophy.
Bosco J, Zhou Z, Gabriëls S, Verma M, Liu N, Miller BK, Gu S, Lundberg DM, Huang Y, Brown E, Josiah S, Meiyappan M, Traylor MJ, Chen N, Asakura A, De Jonge N, Blanchetot C, de Haard H, Duffy HS, Keefe D, Molecular therapy. Methods & clinical development 2021 Jun 21 369-381 -
Transcriptional and cytopathological hallmarks of FSHD in chronic DUX4-expressing mice.
Bosnakovski D, Shams AS, Yuan C, da Silva MT, Ener ET, Baumann CW, Lindsay AJ, Verma M, Asakura A, Lowe DA, Kyba M, The Journal of clinical investigation 2020 May 130 5 2465-2477 -
Inhibition of FLT1 ameliorates muscular dystrophy phenotype by increased vasculature in a mouse model of Duchenne muscular dystrophy.
Verma M, Shimizu-Motohashi Y, Asakura Y, Ennen JP, Bosco J, Zhou Z, Fong GH, Josiah S, Keefe D, Asakura A, PLoS genetics 2019 Dec 15 12 e1008468 -
Inhibition of microRNA-92a increases blood vessels and satellite cells in skeletal muscle but does not improve duchenne muscular dystrophy-related phenotype in mdx mice.
Verma M, Asakura Y, Asakura A, Muscle & nerve 2019 May 59 5 594-602 -
Isometric resistance training increases strength and alters histopathology of dystrophin-deficient mouse skeletal muscle.
Lindsay A, Larson AA, Verma M, Ervasti JM, Lowe DA, Journal of applied physiology (Bethesda, Md. : 1985) 2019 Feb 126 2 363-375 -
Muscle Satellite Cell Cross-Talk with a Vascular Niche Maintains Quiescence via VEGF and Notch Signaling.
Verma M, Asakura Y, Murakonda BSR, Pengo T, Latroche C, Chazaud B, McLoon LK, Asakura A, Cell stem cell 2018 Oct 23 4 530-543.e9 -
CD301b/MGL2+ Mononuclear Phagocytes Orchestrate Autoimmune Cardiac Valve Inflammation and Fibrosis.
Meier LA, Auger JL, Engelson BJ, Cowan HM, Breed ER, Gonzalez-Torres MI, Boyer JD, Verma M, Marath A, Binstadt BA, Circulation 2018 Jun 137 23 2478-2493 -
Improved regenerative myogenesis and muscular dystrophy in mice lacking Mkp5.
Shi H, Verma M, Zhang L, Dong C, Flavell RA, Bennett AM, The Journal of clinical investigation 2013 May 123 5 2064-77 -
Increased angiogenesis and improved left ventricular function after transplantation of myoblasts lacking the MyoD gene into infarcted myocardium.
Nakamura Y, Asakura Y, Piras BA, Hirai H, Tastad CT, Verma M, Christ AJ, Zhang J, Yamazaki T, Yoshiyama M, Asakura A, PloS one 2012 7 7 e41736 -
MyoD gene suppression by Oct4 is required for reprogramming in myoblasts to produce induced pluripotent stem cells.
Watanabe S, Hirai H, Asakura Y, Tastad C, Verma M, Keller C, Dutton JR, Asakura A, Stem cells (Dayton, Ohio) 2011 Mar 29 3 505-16 -
Efficient single muscle fiber isolation from alcohol-fixed adult muscle following β-galactosidase staining for satellite cell detection.
Verma M, Asakura A, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2011 Jan 59 1 60-7 -
Flt-1 haploinsufficiency ameliorates muscular dystrophy phenotype by developmentally increased vasculature in mdx mice.
Verma M, Asakura Y, Hirai H, Watanabe S, Tastad C, Fong GH, Ema M, Call JA, Lowe DA, Asakura A, Human molecular genetics 2010 Nov 19 21 4145-59 -
MyoD regulates apoptosis of myoblasts through microRNA-mediated down-regulation of Pax3.
Hirai H, Verma M, Watanabe S, Tastad C, Asakura Y, Asakura A, The Journal of cell biology 2010 Oct 191 2 347-65 -
Post-mitotic role of nucleostemin as a promoter of skeletal muscle cell differentiation.
Hirai H, Romanova L, Kellner S, Verma M, Rayner S, Asakura A, Kikyo N, Biochemical and biophysical research communications 2010 Jan 391 1 299-304 -
Increased survival of muscle stem cells lacking the MyoD gene after transplantation into regenerating skeletal muscle.
Asakura A, Hirai H, Kablar B, Morita S, Ishibashi J, Piras BA, Christ AJ, Verma M, Vineretsky KA, Rudnicki MA, Proceedings of the National Academy of Sciences of the United States of America 2007 Oct 104 42 16552-7 -
Distortion by sterilisation.
Marshall M, Anaesthesia 1986 Jul 41 7 777
-
Lafora disease gene therapy: EPM2A but not EPM2B overexpression results in Lafora body formation.
Research
- Neurogenetic disorders
- Antisense oligonucleotide (ASO) therapy for Lafora disease
- Natural history for progressive myoclonic epilepsy type 1
- MRI biomarkers for neuronal glycogen storage disorder
Clinical Focus
- Pediatric Epilepsy
- Neurogenetic Disorders
- Pediatric Neuromuscular Disorders
Results: 1 Locations
Children's Medical Center of Dallas
1935 Medical District DriveDallas, Texas 75235 214-730-5437 Directions to Children's Medical Center of Dallas at Children's Medical Center of Dallas, Dallas